Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign. This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state. Immunotherapies are newly developing interventions that modify the patient's immune system to fight cancer, by either directly stimulating rejection‐type processes or blocking suppressive pathways. Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized “immune checkpoint mediator” that interferes with anti‐tumor immune responses. In this review, we focus on CD39 and CD73 ectoenzymes and encompass aspects of the biochemistry of these molecules as well as detailing the distribution and function on immune cells. Effects of CD39 and CD73 inhibition in preclinical and clinical studies are discussed. Finally, we provide insights into potential clinical application of adenosinergic and other purinergic‐targeting therapies and forecast how these might develop in combination with other anti‐cancer modalities. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Immunological Reviews Wiley

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

Loading next page...
 
/lp/wiley/the-ectonucleotidases-cd39-and-cd73-novel-checkpoint-inhibitor-targets-Eg0yngJMkZ

References (682)